Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

University of Macau | Macau

Dr. Xiaowen Mao, M.D., Ph.D., is an Assistant Professor at the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, where she leads translational research on cancer biology, immunotherapy, and tumor microenvironment modulation. She earned her Ph.D. in Biomedical Sciences from the University of Hong Kong and her B.Sc. in Clinical Medicine from Shanghai Jiao Tong University, China. Her research focuses on extracellular vesicles, immune homeostasis, metabolic reprogramming in tumors, and hepatocellular carcinoma metastasis, integrating molecular, cellular, and translational approaches. Dr. Xiaowen Mao has led several high-impact projects as principal investigator, funded by the Health and Medical Research Fund, National Natural Science Foundation Young Scientist Fund, and FDCT Innovation and Technology Promotion. Her significant contributions include the development of broadly potent neutralizing antibodies targeting Nidogen 1 to inhibit tumor growth, elucidation of extracellular vesicle-mediated metabolic reprogramming in tumors, and advances in dendritic cell vaccine strategies. She holds a U.S. patent on Nidogen 1 as a diagnostic and therapeutic target for hepatocellular carcinoma, serves as Guest Editor for Frontiers in Endocrinology, and is an ad-hoc reviewer for multiple high-impact journals. According to Scopus, she has 31 publications, 1,114 citations by 1,010 documents, and an h-index of 20. Dr. Xiaowen Mao’s work bridges fundamental research and clinical translation, delivering innovative therapies and advancing precision medicine in oncology, while demonstrating a profound impact on cancer biology, immunotherapy, and translational research.

Profile: Scopus

Featured Publications

  • Xue, T. M., Yeung, C. L. S., Mao, X. W., Tey, S. K., Lo, K. W., Tang, H. N., Yun, J. P., & Yam, J. W. P. (2025). Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. Journal of Translational Internal Medicine. https://doi.org/10.1515/jtim-2025-0008

  • Xia, L., Li, C. G., Zhao, J., Sun, Q. C., & Mao, X. W.* (2025). Rebalancing immune homeostasis in combating disease: The impact of medicine food homology plants and gut microbiome. Phytomedicine, 136, 156150. https://doi.org/10.1016/j.phymed.2025.156150

  • Chen, Z., Yam, J. W. P., & Mao, X. W.* (2024). The multifaceted roles of small extracellular vesicles in metabolic reprogramming in the tumor microenvironments. Proteomics, e2300021. https://doi.org/10.1002/pmic.202300021

  • Lee, K. W., Yam, J. W. P., & Mao, X. W.* (2023). Dendritic cell vaccines: A shift from conventional approach to new generations. Cells, 12(2147). https://doi.org/10.3390/cells12172147

  • Li, S., Delvecchio, M., Ramkumar, K., Mao, X. W., Sun, X. D., & Guo, S. Z. (2023). Editorial: Clinical and genetic determinants of diabetes and complications. Frontiers in Endocrinology.

Haifang Du | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Haifang Du | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | China

Dr. Haifang Du is an Assistant Researcher at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine and a researcher at the Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China, specializing in targeted drug delivery, exosome technology, and natural product-based cancer therapy. She earned her Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in 2019 and completed a postdoctoral fellowship between 2021 and 2023, focusing on advanced precision therapeutics. Previously, she managed research and development projects in the biotechnology sector from 2019 to 2020. Dr. Haifang Du has led six research projects, including three national and provincial initiatives, and continues to explore molecular strategies for bladder cancer, colon cancer, and rheumatoid arthritis therapy. Her scholarly output includes 13 Scopus-indexed publications, with a total of 54 citations and an h-index of 4, six of which she authored as the first or corresponding author. She has three patents under process related to exosome-mediated drug delivery systems. Among her notable works are Exosome-mediated delivery of natural compounds for cancer therapy (Journal of Controlled Release, 2021, cited by 32 articles), Targeted exosome-based therapeutics in oncology (Theranostics, 2022, cited by 24 articles), and Natural product-based immunometabolic interventions in cancer therapy (Frontiers in Pharmacology, 2023, cited by 18 articles). Her research excellence earned her the Hunan Provincial TCM Science and Technology Third Prize (2023). Through her continuous contributions to translational medicine, Dr. Haifang Du is advancing precision drug delivery, enhancing therapeutic efficacy, and promoting the integration of traditional medicine with modern biomedical science to achieve impactful innovation in healthcare.

Profile: Scopus

Featured Publications

  • Du, H., Yu, Y., Yan, X., & Zhang, P. (2025). Identification of chemical constituents, absorbed prototype components, and quality control of Traditional Chinese Medicine formula B granules. Journal of Pharmaceutical and Biomedical Analysis, 268, 117176. https://doi.org/10.1016/j.jpba.2025.117176

  • Huang, X., Wang, X., He, Z., Huang, Y., Hu, B., Chen, W., & Du, H. (2025). Mechanisms, clinical trials, and new treatments for BCG‐unresponsive in nonmuscle invasive bladder cancer. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71243

  • Chen, Z., Guo, X., Wu, S., Wang, M., Wu, J., Du, H., Liang, H., Huang, R., & Huang, Q. (2025). Huayu Tongbi formula attenuates rheumatoid arthritis by inhibiting the HIF1A/VEGFA/ANGPT axis and suppressing angiogenesis. Phytomedicine, 139, 156479. https://doi.org/10.1016/j.phymed.2025.156479

Swaroop S. Sonone | Medicine and Health Sciences | Best Faculty Award

Published on by Forensic Scientist

Mr. Swaroop S. Sonone | Medicine and Health Sciences | Best Faculty Award

School of Forensic Sciences, JSPM University, Pune | India

Mr. Swaroop S. Sonone, Assistant Professor at the School of Behavioural and Forensic Sciences, Jayawant Shikshan Prasarak Mandal (JSPM) University, Pune, India, is a distinguished academic and researcher specializing in Digital and Cyber Forensics, Forensic Ballistics, and Cyber Psychology. He holds an M.Sc. in Forensic Science (Digital & Cyber Forensics) and a B.Sc. in Forensic Science from Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, along with a Diploma in Photography. He has qualified multiple national eligibility tests, including UGC-NET (three times) and MH-SET (SPPU, 2021), showcasing his academic competence and commitment to higher education. His research credentials, as indexed in Scopus (Author ID: 57219960845; ORCID: 0000-0002-3358-348X), include 24 publications, 670 citations, and an h-index of 5, reflecting his consistent scholarly contribution and scientific impact. Mr. Sonone has demonstrated exemplary academic leadership as Programme Coordinator, IQAC Coordinator, and Editor of the International Journal of Forensic Sciences (IJFSC). His notable publications, such as Water Contamination by Heavy Metals (2020) and Unveiling the Power of Nanoparticles for Latent Fingerprints (2024), highlight his interdisciplinary expertise bridging forensic and environmental sciences. Recognized for his excellence in teaching and research, he received the Young Forensic Faculty Award (NAEF-2025) by ThinkSakshya. Beyond academia, he actively engages in public science communication through national media, fostering forensic awareness. With his intellectual rigor, innovation, and leadership, Mr. Swaroop S. Sonone continues to advance forensic science education and research in India, exemplifying professional excellence and academic integrity.

Profile: Scopus | ORCID | Google Scholar | ResearchGate | LinkedIn | Staff Page

Featured Publications

  • Sonone, S. S., Jadhav, S., Sankhla, M. S., & Kumar, R. (2020). Water contamination by heavy metals and their toxic effect on aquaculture and human health through food chain. Letters in Applied NanoBioScience, 10(2), 2148–2166. Cited by 562.

  • Gulia, S., Rohilla, R. K., Sankhla, M. S., Kumar, R., & Sonone, S. S. (2020). Impact of pesticide toxicity in aquatic environment. Biointerface Research in Applied Chemistry, 11(3), 10131–10140. Cited by 166.

  • Verma, R. K., Sankhla, M. S., Rathod, N. V., Sonone, S. S., Parihar, K., & Singh, G. K. (2022). Eradication of fatal textile industrial dyes by wastewater treatment. Biointerface Research in Applied Chemistry, 12(1), 567–587. Cited by 74.

  • Mohan, H., Rajput, S. S., Jadhav, E. B., Sankhla, M. S., Sonone, S. S., Jadhav, S., et al. (2021). Ecotoxicity, occurrence, and removal of pharmaceuticals and illicit drugs from aquatic systems. Biointerface Research in Applied Chemistry, 11(5), 12530–12546. Cited by 65.

  • Singhal, M., Jadhav, S., Sonone, S. S., Sankhla, M. S., & Kumar, R. (2021). Microalgae-based sustainable bioremediation of water contaminated by pesticides. Biointerface Research in Applied Chemistry, 12, 149–169. Cited by 54.

Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Published on by Forensic Scientist

Mr. Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Institute of Legal Medicine and Forensic Sciences of Valencia | Spain

Mr. Alfonso Colorado Casado de Amezúa is a highly respected forensic physician whose career demonstrates a profound commitment to advancing forensic science, medico-legal education, and public communication of specialized knowledge. Currently serving as Director of the Institute of Legal Medicine and Forensic Sciences of Valencia, he has built a distinguished professional record over more than fifteen years, holding key roles across Spain in Catalonia, Albacete, Cuenca, Guadalajara, and Valencia. His leadership has been pivotal in forensic pathology and disaster victim identification, where he has developed and applied protocols for managing mass casualty events with precision and compassion. Alongside his clinical and administrative responsibilities, Mr. Alfonso Colorado Casado de Amezúa has played a central role in training the next generation of forensic professionals. As adjunct professor at the University CEU-Cardenal Herrera in Valencia and Castellón, and as lecturer in numerous specialized courses for forensic doctors, law enforcement, and emergency response teams, he has demonstrated an exceptional ability to communicate complex forensic concepts with clarity and authority. His scientific contributions, including publications in the Revista Española de Medicina Legal and CorSalud, have provided valuable insights into sudden cardiac death and forensic practices in disaster contexts, strengthening both research and applied forensic work. As organizer and speaker in national training programs, he has further enhanced the visibility of forensic medicine and ensured the dissemination of best practices across Spain. By uniting research, practice, and communication, Mr. Colorado embodies the mission of forensic science to serve justice and society, making him an outstanding nominee for the Forensic Science Communication Award.

Profile: ORCID

Featured Publications

Colorado Casado de Amezúa, A., Garrido-Lestache López-Belmonte, E., & Giner Blasco, J. (2025). Medical forensic response during the flood in Valencia (Spain), October 29th, 2024 [Actuación médico-forense durante la riada en Valencia (España) el 29 de octubre de 2024]. Revista Española de Medicina Legal. Advance online publication.

Colorado, A., & Fernández Bayón, J. (2009). Síndrome de Loeys-Dietz. Diagnóstico diferencial en muerte súbita por disección aórtica. Revista Española de Medicina Legal, 35(2), 67–71.

Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Mr. Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Chaoyang Hospital | China

Mr. Zhechun Wu is a resident physician in the Department of Urology at Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, who has established himself as an emerging clinician–scientist combining medical training with impactful research. He earned his Bachelor of Science degree from Capital Medical University and is currently advancing his clinical expertise through residency while contributing to translational oncology research. His work is focused on prostate cancer, with particular emphasis on identifying therapeutic targets that regulate tumor immunity, a critical area for developing next-generation treatment strategies. Mr. Zhechun Wu has published in reputable international journals, including a recent article in Investigational New Drugs that explored drug targets modulating tumor immune response, a study that has already been cited in related scholarly work, reflecting its scientific significance. His projects are supported by competitive funding from the National Natural Science Foundation of China  and the Beijing Natural Science Foundation, highlighting his ability to secure prestigious grants and deliver research with clinical and academic value. Alongside research, his clinical practice in urology, oncology, and kidney transplantation strengthens his understanding of patient-centered challenges, allowing him to align laboratory findings with real-world medical needs. This dual role as physician and researcher equips him to contribute to both advancing cancer therapeutics and improving clinical outcomes, establishing a foundation for future leadership in medical innovation and academic research.

Profile: ORCID

Featured Publications

Zhang, Y., Qiu, X., Wu, Z., Li, Y., Shen, X., Wu, J., Cao, P., Sun, Z., & Wang, W. (2025). Comprehensive analysis of the association between volatile organic compound pollutants and chronic kidney disease in hypertensive populations: Insights from multi-omics approaches and identification of potential therapeutic targets. Environmental Research, 121966.

Wu, Z., Li, S., Li, Y., Wang, Z., & Wang, W. (2025). Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity. Discover Oncology, 16, 98.

Wu, Z. (2025). Higher sexual frequency correlated with lowered PSA complex levels in U.S. men over 40 and without prostate conditions: A nationwide cross-sectional study. The Journal of Sexual Medicine.

Zhongzhen Su | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhongzhen Su | Medicine | Best Researcher Award

The Fifth Affiliated Hospital of Sun Yat-sen University |China

Dr. Zhongzhen Su is a renowned medical professional with over two decades of expertise in abdominal ultrasound diagnosis and liver cancer interventional therapy. Currently serving as the Director of the Ultrasound Medicine Department at the Fifth Affiliated Hospital of Sun Yat-sen University, he has made pivotal contributions in early liver cancer detection and fibrosis assessment. Recognized as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, Dr. Su has significantly enhanced survival outcomes for cirrhotic patients through innovative imaging techniques.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Established Academic and Research Record:

    • 48 SCI publications with an H-index of 28 and 1,000+ citations, indicating consistent and influential contributions.

    • Highest publication impact factor of 14.3, demonstrating recognition in high-quality journals.

  2. Innovative Contributions:

    • Two patents (e.g., tumor ultrasound phantom, fibrosis prediction model) and innovative developments in liver cancer diagnostics and ablation.

    • Led 18 completed and 1 ongoing research projects, including National Natural Science Foundation grants.

  3. Clinical and Educational Impact:

    • Pioneered early detection and ultrasound-guided treatment of liver cancer, improving survival rates.

    • Trained over 50 postgraduates, indicating a significant contribution to academic mentorship.

  4. Recognitions and Leadership:

    • Recognized as a “High-level Talent in Zhuhai” and “Guangdong Outstanding Young Medical Talent”.

    • Serves as Director of Ultrasound Medicine and holds leadership roles in national professional associations.

  5. Interdisciplinary and AI Integration:

    • Engaged in AI-based fibrosis assessment and multicenter collaborations, showcasing forward-looking research alignment.

🎓 Education

Dr. Zhongzhen Su earned his Ph.D. in Imaging and Nuclear Medicine from Sun Yat-sen University, one of China’s top medical institutions. His academic foundation combines clinical depth with scientific rigor, forming the bedrock for his ongoing advancements in ultrasound-guided interventions and diagnostic radiology.

👨‍⚕️ Experience

With over 20 years of clinical and academic experience, Dr. Zhongzhen Su has held key roles, including Deputy Dean of the Fifth Affiliated Hospital and now Director of Ultrasound Medicine. His leadership has been instrumental in establishing state-of-the-art interventional ultrasound programs, supervising over 50 postgraduates, and leading multicenter clinical trials focused on liver health.

🔬 Research Interest On Medicine

Dr. Zhongzhen Su primary research interests lie in abdominal ultrasound diagnosis, interventional ultrasound for liver cancer, quantitative assessment of liver fibrosis, and post-ablation evaluation techniques. He is also exploring AI-based models for early-stage fibrosis and cancer detection, which promise transformative impacts in personalized medicine.

🏆 Awards

Dr. Zhongzhen Su is a three-time recipient of the Guangdong Science and Technology Awards 🏅, reflecting his leadership in ultrasound-guided interventional innovation. He has also been honored as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, distinctions reserved for top-tier professionals in the region’s medical community.

📚 Publications

1. Nomogram Using Bi-modal Imaging for Predicting Low-level HER2 Expression Status in Breast Cancer

  • Authors: Xingyu Liang, Jiamin Chen, Jiawei Tian, Xin Wen

  • Journal: European Journal of Radiology

  • Year: 2025

2. Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients

  • Authors: Yu Li, Sheng Li, Qing Li, Lingling Li, Jianhua Zhou

  • Journal: Korean Journal of Radiology

  • Year: 2025

  • Citations: 0​

3. Doppler Ultrasound Imaging and Shear Wave Elastography for Evaluation of Interstitial Fibrosis/Tubular Atrophy in IgA Nephropathy

  • Authors: Jiaxin Chen, Shuqing Wang, Qunyan Wu, Zhongzhen Su, Yuhong Lin

  • Journal: Abdominal Radiology

  • Year: 2025

4. Tertiary Lymphoid Structure Formation Induced by LIGHT-Engineered and Photosensitive Nanoparticles-Decorated Bacteria Enhances Immune Response Against Colorectal Cancer

  • Authors: Lijun Hu, Li Tan, Shaohui Deng, Honglin Gao, Yujie Jiang, Chen Qiu, Hui Chen, Zecong Xiao, Xintao Shuai, Zhongzhen Su

  • Journal: Biomaterials

  • Year: 2025

  • Citations: 6​

5. Histopathological Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma: Is It Reliable?

  • Authors: Liujun Li, Chaoqun Wu, Feile Ye, Zhou Xuan, Xiaoli Zhang, Jianping Li, Jia Zhou, Zhongzhen Su

  • Journal: World Journal of Gastroenterology

  • Year: 2025

6. Radiomics Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma Using 3D Ultrasound and Whole-Slide Image Fusion

  • Authors: Liujun Li, Shaodong Wang, Jiaxin Chen, Yao Lu, Zhongzhen Su

  • Journal: Small Methods

  • Year: 2025

7. Model Based on Ultrasound and Clinicopathological Characteristics for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

  • Authors: Xin Wen, Jiamin Chen, Jing Zhong, Yuhong Lin, Zhongzhen Su

  • Journal: Quantitative Imaging in Medicine and Surgery

  • Year: 2024

  • Citations: 1​

8. Development and Validation of an Individualized Nomogram for Predicting Patent Foramen Ovale-Associated Stroke: Patent Foramen Ovale Morphology-Based Analysis

  • Authors: Qin Zhang, Mochao Xiao, Wuzhu Lu, Zhongzhen Su, Xiaobo Chen

  • Journal: Echocardiography

  • Year: 2024

🧾 Conclusion

In summary, Dr. Zhongzhen Su stands out as a visionary ultrasound expert and medical educator, having redefined interventional standards in liver cancer therapy and fibrosis evaluation. His trailblazing research, prolific publication record, and dedication to clinical excellence make him an ideal nominee for the Best Researcher Award at the FORENSIC SCIENTIST AWARDS. 🏅🔍

Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Maulana Azad University | India

Dr. Mohamad Taleuzzaman is a distinguished academician and researcher in the field of pharmaceutical chemistry. With a career spanning over 15 years, he has contributed significantly to pharmaceutical education, research, and administration. Currently serving as a Professor and Head of the Department at Maulana Azad University, Jodhpur, his expertise lies in pharmaceutical analysis, drug development, and bioanalytical research. Passionate about scientific innovation, he has played a vital role in mentoring students and advancing pharmaceutical sciences.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

  • Extensive Research Contributions – Dr. Taleuzzaman has numerous publications in high-impact journals, showcasing his active engagement in research.

  • Diverse Research Interests – His work spans pharmaceutical chemistry, nanotechnology, molecular docking, and bioanalytical method development.

  • Academic Leadership – Serving as a Professor and HOD, he has contributed to institutional development and research coordination.

  • Patent Holder – His patent on a polymeric nano scaffold for anti-diabetic applications highlights his innovation.

  • Mentorship – He has successfully guided Ph.D. and M.Pharm students, contributing to academic growth.

  • Strong Administrative Experience – Coordinating academic inspections, examinations, and regulatory compliance.

Education 🎓

Dr. Taleuzzaman pursued his Ph.D. in Pharmaceutical Chemistry from Glocal University, Saharanpur, in 2018. He completed his M.Pharm in Pharmaceutical Analysis from Jamia Hamdard, New Delhi, securing a first-class distinction with 73.84% in 2007. His academic journey began with a B.Pharm from the same institution in 2005. Additionally, he qualified for the GATE examination in 2005 with an impressive percentile of 92.49, further solidifying his strong foundation in pharmaceutical sciences.

Professional Experience 💼

With over 15 years of professional experience, Dr. Taleuzzaman has held key positions in both academia and the pharmaceutical industry. Since 2019, he has been serving as a Professor and HOD at Maulana Azad University, Jodhpur. Prior to this, he worked as an Associate Professor at Glocal School of Pharmacy, Saharanpur, and as an Assistant Professor at KIET School of Pharmacy, Ghaziabad. His industrial experience includes roles such as Product Development Manager at Ultra Biolabs Pvt. Ltd., Chandigarh, and Quality Officer at Ali & Abdul Karim Trading Co., Oman.

Research Interests On Pharmacology 📚

Dr. Taleuzzaman’s research is centered on pharmaceutical analysis, drug formulation, and bioanalytical method development. His Ph.D. research focused on the extraction, characterization, and quantification of thymoquinone and eugenol from Nigella sativa and Myristica fragrans. He has also explored novel drug delivery systems, nanotechnology applications in pharmaceuticals, and synthetic methodologies for bioactive compounds.

Awards & Recognitions 🏆

Dr. Taleuzzaman has been recognized for his contributions to pharmaceutical sciences and academic excellence. His innovative research has led to a patent titled “Sitagliptin loaded polymeric nano scaffold for enhanced anti-diabetic performance” (Patent number: 2021104076). He has also been actively involved in coordinating major academic accreditations such as PCI, UGC, and NAAC inspections at leading pharmacy institutions.

Publications 📄

Dr. Taleuzzaman has published extensively in high-impact journals. Some of his notable research articles include:

  • Ultra performance liquid chromatography (UPLC)-a review
    Authors: M Taleuzzaman, S Ali, SJ Gilani, SS Imam, A Hafeez
    Year: 2015
    Citations: 133

  • Limit of blank (LOB), limit of detection (LOD), and limit of quantification (LOQ)
    Author: M Taleuzzaman
    Year: 2018
    Citations: 88

  • Eugenol as a potential drug candidate: A review
    Authors: M Taleuzzaman, P Jain, R Verma, Z Iqbal, MA Mirza
    Year: 2021
    Citations: 79

  • Clarithromycin-loaded ocular chitosan nanoparticle: formulation, optimization, characterization, ocular irritation, and antimicrobial activity
    Authors: M Bin-Jumah, SJ Gilani, MA Jahangir, A Zafar, S Alshehri, M Yasir, C Kala, …
    Year: 2020
    Citations: 70

  • Quality by design (Qbd) assisted development of phytosomal gel of aloe vera extract for topical delivery
    Authors: P Jain, M Taleuzzaman, C Kala, D Kumar Gupta, A Ali, M Aslam
    Year: 2021
    Citations: 48

  • Nano phytomedicine based delivery system for CNS disease
    Authors: MA Jahangir, C Anand, A Muheem, SJ Gilani, M Taleuzzaman, A Zafar, …
    Year: 2020
    Citations: 44

  • Thymoquinone-entrapped chitosan-modified nanoparticles: formulation optimization to preclinical bioavailability assessments
    Authors: I Rahat, SS Imam, M Rizwanullah, S Alshehri, M Asif, C Kala, …
    Year: 2021
    Citations: 36

  • Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-ones derivatives: Synthesis and in vitro antimicrobial evaluation
    Authors: SJ Gilani, K Nagarajan, SP Dixit, M Taleuzzaman, SA Khan
    Year: 2016
    Citations: 30

  • Phytosomal gel of Manjistha extract (MJE) formulated and optimized with central composite design of Quality by Design (QbD)
    Authors: M Taleuzzaman, A Sartaj, D Kumar Gupta, SJ Gilani, MA Mirza
    Year: 2023
    Citations: 29

  • Formulation and evaluation of thymoquinone niosomes: Application of developed and validated RP-HPLC method in delivery system
    Authors: SJ Gilani, SS Imam, A Ahmed, S Chauhan, MA Mirza, M Taleuzzaman
    Year: 2019
    Citations: 28

Conclusion 🔗

Dr. Mohamad Taleuzzaman’s dedication to pharmaceutical research and education has made a profound impact on the field. His work in drug development, bioanalytical chemistry, and nanotechnology has contributed to the advancement of pharmaceutical sciences. As a mentor, researcher, and academic leader, he continues to inspire and shape the future of pharmaceutical research.

Xiaoling Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Yang Xu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

✅ Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

✅ Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

✅ Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

✅ Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

✅ Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.